Natixis’s Pfizer PFE Stock Holding History

Natixis’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-103	Closed	-$5K	–	1152
2022 Q2	$5K	Buy	+103	New	+$5.25K	﹤0.01%	1099

Other funds holding PFE

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Natixis's PFE Position: Q3 2026 in Review

Natixis increased its Pfizer (PFE) stake by 144% in Q3 2026, buying an estimated $24.3M and bringing the position to 1,545,610 shares worth $44.1M. The position accounts for 0.16% of the portfolio, ranked #92.

Natixis first reported a position in PFE in Q2 2013 and has held it in 51 quarters since. The position peaked at $258M in Q2 2019. 2,002 funds tracked by Wall St. Rank hold PFE as of Q3 2026.

Natixis held 1,545,610 shares of Pfizer worth $44.1M as of Q3 2026.
Natixis bought 913,293 Pfizer shares in Q3 2026, an estimated $24.3M.
Pfizer made up 0.16% of Natixis's portfolio in Q3 2026, its #92 holding.
Natixis first reported a position in Pfizer in Q2 2013 and has held it in 51 quarters since.
Natixis's Pfizer position peaked at $258M in Q2 2019.
2,002 funds tracked by Wall St. Rank held Pfizer as of Q3 2026.

Based on Natixis's 13F filing for Q3 2026, filed 6 Nov 2026.